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Abstract
Background: Bacteremia, or bloodstream infection (BSI), is a leading cause of death among patients with certain
types of cancer. A previous study reported that intestinal domination, defined as occupation of at least 30 % of the
microbiota by a single bacterial taxon, is associated with BSI in patients undergoing allo-HSCT. However, the impact
of the intestinal microbiome before treatment initiation on the risk of subsequent BSI remains unclear. Our objective
was to characterize the fecal microbiome collected before treatment to identify microbes that predict the risk of BSI.
Methods: We sampled 28 patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic stem cell
transplantation (HSCT) prior to administration of chemotherapy and characterized 16S ribosomal RNA genes using
high-throughput DNA sequencing. We quantified bacterial taxa and used techniques from machine learning to identify
microbial biomarkers that predicted subsequent BSI.
Results: We found that patients who developed subsequent BSI exhibited decreased overall diversity and decreased
abundance of taxa including Barnesiellaceae, Coriobacteriaceae, Faecalibacterium, Christensenella, Dehalobacterium,
Desulfovibrio, and Sutterella. Using machine-learning methods, we developed a BSI risk index capable of predicting BSI
incidence with a sensitivity of 90 % at a specificity of 90 % based only on the pretreatment fecal microbiome.
Conclusions: These results suggest that the gut microbiota can identify high-risk patients before HSCT and that
manipulation of the gut microbiota for prevention of BSI in high-risk patients may be a useful direction for future
research. This approach may inspire the development of similar microbiome-based diagnostic and prognostic models
in other diseases.
Keywords: Bloodstream infection, Chemotherapy, Intestinal microbiome, Prediction
Background
Hematopoietic stem cell transplantation (HSCT) is com-
monly applied as curative treatment in patients with
hematological malignancy [1]. A frequent side effect of
myeloablative doses of chemotherapy used during the
HSCT procedure is gastro-intestinal (GI) mucositis [2].
A recent model, introduced by Sonis, described a
process for bacterial infection due to GI mucositis [3]. It
includes an ulcerative phase with increased permeability
and damage to the intestinal mucosal barrier. This pro-
motes bacterial translocation, defined as the passage of
bacteria from the GI tract to extra-intestinal sites, such
as the bloodstream [4]. Bacteremia, or bloodstream
infection (BSI), remains a common life-threatening com-
plication with well-documented morbidity and mortality
in patients with cancer [5]. In a recent study, the overall
rate was 9.1 BSIs per 1000 patient-days with a 28-day
case mortality rate of 10 % and 34 % in case of P. aerugi-
nosa. [6]. Another study reported that the overall inci-
dence of BSI was 7.48 episodes per 1000 hospital stays
for neutropenic hematological patients, with 11 % of the
patients requiring intensive care unit admission and
resulting in an overall case-fatality rate at 30 days of
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12 % [7]. Furthermore, BSI is particularly frequent
during the early transplant period due to the intensive
chemotherapy regimen administered prior to HSCT
[8], but there is currently no way to predict or pre-
vent it.
While the model of pathobiology of mucositis reported
above is silent on the role of the intestinal microbiome,
Van Vliet et al. proposed a potential role for the intestinal
microbiome in BSI [9]. A previous study reported that in-
testinal domination, defined as occupation of at least 30 %
of the microbiota by a single bacterial taxon, is associated
with BSI in patients undergoing allo-HSCT [10].
However, the impact of the intestinal microbiome
before treatment initiation on the risk of subsequent BSI
remains poorly studied. We hypothesized that patients
who entered the hospital with a diverse microbiome
dominated by operational taxonomic units (OTUs) that
were previously associated with gut homeostasis would
be less likely to acquire a BSI. Thus, the objective of our
work was to use fecal samples collected prior to chemo-
therapy to identify biomarkers in the fecal microbiome
that predict the risk of subsequent BSI.
Methods
Study patients and fecal sample collection
Participants with non-Hodgkin lymphoma (NHL) were
recruited in the hematology department of Nantes
University Hospital, France, as reported in our previ-
ous study [11]. Briefly, in this study, we excluded pa-
tients with a history of inflammatory bowel diseases,
those exposed to probiotics, prebiotics, or broad-spectrum
antibiotics, and those administered nasal-tube feeding or
parenteral nutrition in the month prior to initiation of the
study. Participants received the same myeloablative condi-
tioning regimen for 5 consecutive days, including high-
dose Carmustine (Bis-chloroethylnitrosourea), Etoposide,
Aracytine, and Melphalan, and allogeneic HSCT occurred
on the seventh day. Most of the participants received anti-
biotic prophylaxis before the conditioning therapy based
on penicillin V and/or cotrimoxazole, which was stopped
on the day of the hospital inpatient admission. Therefore,
no patient had ongoing antibiotic treatment at the time
of the sample collection and all the patients stopped
the antibiotic treatment on the same day: hospital in-
patient admission (Day 0).
BSI, the endpoint of the study, was assessed during in-
patient HSCT hospitalization, following standard Centers
for Disease Control and Prevention definitions of a
laboratory-confirmed bloodstream infection. We col-
lected a fecal sample from all participants. The fecal
sample was collected on hospital inpatient admission
(Day 0), prior to administration of the high-dose
chemotherapy conditioning the transplant, and was
stored at −80 °C until analysis.
DNA extraction, PCR amplification of V5-V6 region of
bacterial 16S ribosomal RNA genes, and pyrosequencing
The genomic DNA extraction procedure was based on
the QIAamp® DNA Stool Minikit (Qiagen, Hilden,
Germany), as reported in our previous study [11]. Then,
for each sample, we amplified 16S ribosomal RNA
(rRNA) genes, using a primer set corresponding to
primers 784 F (AGGATTAGATACCCTGGTA) and
1061R (CRRCACGAGCTGACGAC), targeting the V5
and V6 hypervariable 16S rRNA gene region (~280 nt
region of the 16S rRNA gene) [12]. Pyrosequencing was
carried out using primer A on a 454 Life Sciences
Genome Sequencer FLX instrument (454 Life Sciences-
Roche, Brandford, CT, USA) with titanium chemistry at
DNAVision (Charleroi, Belgium).
Sequence analysis
The 16S rRNA raw sequences were analyzed with the
QIIME 1.8.0 software [13]. Sequences were assigned to
97 % ID OTUs by comparing them to the Greengenes
reference database 13_8 [14]. We represented beta
diversity, based on Unweighted UniFrac distances, with
principal coordinate analysis (PCoA). We applied the
PERMANOVA method on the previously obtained dis-
similarity matrices to determine whether communities
differ significantly between fecal samples of patients who
ultimately did or did not develop BSI. PERMANOVA
was performed using 1000 permutations to estimate
p values for differences among patients with different
BSI status. We computed alpha diversity metrics,
using both non-phylogeny and phylogeny-based met-
rics, and tested differences in alpha diversity with a
Monte Carlo permuted t-test. We performed a non-
parametric t-test with 1000 permutations to calculate
the p values for differences among patients with dif-
ferent BSI status. We used PICRUSt, a computational
approach to predict the functional composition of a
metagenome using marker gene data (in this case the 16S
rRNA gene) and a database of reference genomes [15].
Statistical analysis
We developed a BSI risk index corresponding to the dif-
ference between a patient’s total relative abundance of
taxa associated with protection from BSI and the pa-
tient’s total relative abundance of taxa associated with
development of a subsequent BSI. In detail, we included
in the BSI risk index all the taxa with a false discovery
rate (FDR)-corrected p value less than 0.15. FDR was ap-
plied at each taxonomy level separately. For the predict-
ive panel, the primary assessment of the relevance of the
taxa is the accuracy of the predictions rather than the
significance of the individual features, although the FDR
threshold used still has the standard interpretation for
statistical significance. The BSI risk was calculated using
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the sum of relative abundances of the taxa that were sig-
nificantly associated with BSI minus the sum of the rela-
tive abundances of the taxa that were associated with
protection from BSI (Additional file 1). Importantly, we
assessed the accuracy of predictions by predicting the
risk index for a given patient using predictive taxa iden-
tified using only other patients, in order to avoid infor-
mation leak. The leave-one-out procedure consisted of
holding a single patient out from the entire analysis at
each iteration, in which the held-out sample represented
a novel patient from the same population. This assessed
the ability of the classifier to predict BSI risk for one pa-
tient based on their pre-chemotherapy microbiome,
using a model trained only on the pre-chemotherapy
microbiomes of other patients. We then retrained the
model one last time on the entire dataset to report the
taxa included in the predictive panel. To assess variabil-
ity in the predictive strength of the model depending on
training data selection, we plotted receiver-operating
characteristic (ROC) curves and computed the area
under the curve (AUC) values on ten sets of predictions
obtained from tenfold cross-validation using ROCR
package in R. In parallel to the BSI risk index analysis,
we also performed Random Forest (RF) classification
with 500 trees and tenfold cross-validation [16].
To determine whether differences in sequencing depth
across samples could be a confounding factor in our es-
timates of diversity, we compared sequencing depths be-
tween BSI and non-BSI patients using a Mann–Whitney
U test. To evaluate the effects of different sequencing
depth across samples on diversity estimates resulting
from OTU picking [17], we subsampled the original se-
quencing data to an even depth of 3000 sequences per
sample prior to picking OTUs. We then re-calculated
alpha diversity (observed species, phylogenetic diversity)
and performed a Mann–Whitney U test to compare
alpha diversity between BSI and control participants. We
repeated this subsampling procedure at 2000 and 1000
sequences per sample.
Results
Patient and fecal sample characteristics
The study included 28 patients with NHL undergoing
allogeneic HSCT. Of the fecal samples collected, a total
of 280,416 high-quality 16S rRNA-encoding sequences
were identified, representing 3857 OTUs. Since samples
contained between 3041 and 26,122 sequences, diversity
analyses were rarefied at 3041 sequences per sample
(Additional file 2). We identified the reported taxon as-
sociations using non-rarefied data normalized to relative
abundances.
BSI was reported in 11 patients (39 % [24–58 %]), at a
mean ± standard deviation of 12 ± 1 days after sample
collection. Two patients (18.2 % [5.1–47.7 %]) developed
Enterococcus BSI, four (36.4 % [15.0–64.8 %]) developed
Escherichia coli BSI, and five (45.5 % [21.3– 72.0 %]) pa-
tients developed other Gammaproteobacteria BSI. Here
and henceforth, qualitative data are reported as percent-
age [95 % confidence interval] and quantitative data are
reported as medians [25–75 % percentile] unless other-
wise noted. As detailed in Table 1, antibiotic prophylaxis
based on penicillin V and/or cotrimoxazole was received
before admission in nine (82 %, 52–95) BSI patients and
15 (88 %, 65–97) patients without BSI (Fisher’s exact
test, two-sided p value = 0.99). Importantly, antibiotic
prophylaxis was not associated with a specific micro-
biome composition (Additional file 3). Moreover, all the
patients received chemotherapy and broad spectrum
antibiotics before the HSCT hospitalization, by a median
delay of 4 months.
Decreased diversity in pre-chemotherapy fecal samples
associated with subsequent BSI
PCoA of fecal samples collected prior to treatment,
based on 16S rRNA sequences of unweighted UniFrac
distance metric, showed differences between fecal
samples of patients who did or did not develop BSI
(PERMANOVA, two-sided p value = 0.01) (Fig. 1). Dif-
ferences were not significant when using weighted
UniFrac. In our previously published studies we have
found consistently that at the level of OTUs, unweighted
UniFrac provides better power than weighted UniFrac
for discriminating experimental groups. We also used a
standard machine-learning method to verify the robust-
ness of discriminating fecal samples from patients who
did or did not develop BSI. Supervised learning using
Random Forests accurately assigned samples to their
source population based on taxonomic profiles at the
family level (82.1 % accuracy or number of correct
classifications divided by total number of classifications,
2.6 times better than the baseline error rate for ran-
dom guessing). However, this was outperformed by
the risk index approach according to leave-one-out
cross-validation.
Alpha diversity in fecal samples from patients who de-
veloped BSI was significantly lower than alpha diversity
from patients who did not develop subsequent BSI, with
reduced evenness (Shannon index, Monte Carlo per-
muted t-test two-sided p value = 0.004) and reduced
richness (Observed species, Monte Carlo permuted t-test
two-sided p value = 0.001) (Fig. 2). Further, these differ-
ences in richness between patients who developed BSI
and patients who did not develop subsequent BSI are
robust to rarefaction, being detected with as few as 500
reads per sample (Shannon index, Monte Carlo permuted
t-test two-sided p value = 0.007; Observed species,
Monte Carlo permuted t-test two-sided p value = 0.005,
Additional file 4).
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In order to determine whether differential sequencing
depth between the BSI and non-BSI groups could be
confounding our analysis by affecting diversity estimates
resulting from OTU picking, we first verified that
sequencing depth was not associated with BSI status
(p = 0.9263, Mann–Whitney U test). Therefore, we do
not expect sequencing depths to influence our results.
We also subsampled the input sequences to achieve even
depth per sample prior to performing OTU picking and
then re-picked OTUs to determine whether differences in
sequencing depth were affecting our OTU diversity. We
did this at 1000, 2000, and 3000 sequences per sam-
ple. In each case, the groups remained significantly
different (p <0.01, Mann–Whitney U test), with the
BSI patients having lower diversity microbiomes in
their pretreatment samples (Additional file 4).
A novel microbiome-based BSI risk index predicts BSI
We identified a panel of 13 microbes that were differen-
tiated between patients who did and did not develop
BSI (Mann–Whitney U test, FDR-corrected two-sided
p value <0.15). Fecal samples collected prior to treatment
from the patients who developed subsequent BSI ex-
hibited significantly decreased abundance of members
of Bacteroides (Barnesiellaceae, Butyricimonas), Firmi-
cutes (Christensenellaceae, Faecalibacterium, Oscillos-
pira, Christensenella, Dehalobacterium), Proteobacteria
(Desulfovibrio, Sutterella, Oxalobacter) and Actinobacteria
(Coriobacteriaceae) compared to patients who did not
Table 1 Characteristics of the study population
BSI group (n = 11) No BSI group (n = 17) p value
Age (years) 59 [46–61] 54.5 [45–60] 0.80
Sex (male) 7 (64 %, 35–85) 13 (76 %, 53–90) 0.75
Body mass index 24 [22–28] 25 [24–28] 0.90
Antibiotic prophylaxis 9 (82 %, 52–95) 15 (88 %, 65–97) 0.99
Penicillin V 8 (72 %, 49–92) 6 (35 %, 17–59) 0.12
Cotrimoxazole 7 (63 %, 36–85) 12 (70 %, 47–87) 0.99
ICU admission 1 (9.0 %, 1.6–37.7) 2 (11.8 %, 2.0–37.8) 0.99
Days of neutropenia 9.0 [8.5-10.0] 10 [9–11] 0.27
Previous chemotherapy (months) 4.0 [3–7.5] 4 [3–5] 0.44
Previous antibiotic treatment (months) 4.0 [2–5] 4 [3–5] 0.66
Other comorbidities, hypertension 4 (36.4 % 12.7–68.4) 2 (11.8 %, 2.0–37.8) 0.28
Diffuse large B-cell lymphoma 9 (81.8 %, 47.8–96.8) 10 (58.9 %, 36.0–78.4) 0.39
Follicular lymphoma 0 (0.0 %, 0.0–25.8) 2 (11.8 %, 2.0–37.8) 0.67
Burkitt lymphoma 0 (0.0 %, 0.0–25.8) 1 (5.9 %, 1.0–27.0) 0.99
Mantle cell lymphoma 2 (57.1 %, 25.0–84.2) 3 (17.6 %, 6.2–41.0) 0.39
Anaplastic large cell lymphoma 0 (0.0 %, 0.0–25.8) 1 (5.9 %, 1.0–27.0) 0.99
BSI, Bloodstream infection; ICU, Intensive Care Unit; NHL, non-Hodgkin lymphoma
Quantitative data are shown as median [1st and 3rd quartile]; fractional data are shown as mean [lower-upper bounds of 95 % confidence interval]
Fig. 1 Beta-diversity comparisons of the gut microbiomes of fecal
samples from samples collected prior to treatment in patients who
developed subsequent BSI (n = 11) and in patients who did not
develop subsequent BSI (n = 17). The first three axes are shown
of principal coordinate analysis (PCoA) of Unweighted UniFrac
distances between patient bacterial communities. The proportion of
variance explained by each principal coordinate axis is denoted in
the corresponding axis label. The plot shows a significant separation
between fecal samples from patients who developed subsequent
BSI and in patients who did not develop subsequent BSI
(PERMANOVA, p = 0.01)
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develop subsequent BSI. The patients who developed
BSI exhibited significantly higher abundance of Erysi-
pelotrichaceae and Veillonella in fecal samples col-
lected prior to treatment compared to patients who
did not develop subsequent BSI (Fig. 3, Additional
files 5, 6, and 7).
We tested the individual ability of these microbes to
discriminate between patients who did and did not
develop subsequent BSI. Based on ROC curve analyses,
we found that Barnesiellaceae yielded a ROC-plot AUC
value of 0.94, Christensenellaceae yielded a ROC-plot
AUC value of 0.86, and Faecalibacterium yielded a
ROC-plot AUC value of 0.84 (Additional file 8).
To assess the predictive accuracy of this method for
identifying the panel of bacteria, we then performed
leave-one-out cross-validation, a rigorous statistical ap-
proach from machine learning, wherein the entire
model is retrained on n-1 samples to predict the BSI
risk of the held-out sample, and then the process is
repeated for each sample. The predicted risk indices
were highly differentiated between patients who did
and did not develop BSI (Mann–Whitney U p value
= 0.008). Median BSI risk index was −0.01 (IQR =
0.02) in patients who develop subsequent bacteremia
and median BSI risk index was −0.05 (IQR = 0.02) in
patients who did not develop BSI (Mann–Whitney U test,
two-sided p value <0.001) (Fig. 4a). A negative risk index
simply means that the protection-associated taxa were
more abundant than the risk-associated bacteria, but not
necessarily that the patient’s risk score was sufficiently low
to be classified as low risk. ROC curve analysis showed
that the BSI risk index was a strong predictor of the onset
of subsequent BSI, with an AUC of 0.94 (Fig. 4b). In the
leave-one-out classification, we determined that a BSI risk
index classification threshold of −0.02 best predicts BSI in
a new patient, yielding a sensitivity of 90 % at a specificity
of 90 %. Importantly, the risk values shown in Fig. 4a are
entirely predicted for each participant using a panel of mi-
crobes retrained from scratch only on the other partici-
pants. We then retrained the model one last time on the
entire dataset to report the taxa included in the final pre-
dictive panel (Fig. 3).
Clinical history does not predict BSI
Association between clinical data (age, sex, previous
antibiotic treatment received, type of antibiotic treat-
ment, delay of the previously received antibiotic treat-
ment, previous chemotherapy received, and delay of the
previously received chemotherapy) and BSI was tested
using a univariate and a multivariate logistic regression
Fig. 2 Alpha-diversity indices in samples collected prior to treatment in patients who developed subsequent BSI (red, n = 11) versus samples
collected prior to treatment in patients who did not develop subsequent BSI (blue, n = 17), based on phylogenetic and non-phylogenetic richness.
Analyses were performed on 16S rRNA V5 and V6 regions data, with a rarefaction depth of 3041 reads per sample. Whiskers in the boxplot represent
the range of minimum and maximum alpha diversity values within a population, excluding outliers. Monte-Carlo permutation t-test: *p <0.05;
**p <0.01; and ***p <0.001. Boxplots denote top quartile, median, and bottom quartile. BSI, Bloodstream infection. Patients who developed
a subsequent BSI had significantly lower microbial richness compared with patients who did not develop subsequent BSI
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with a backward step-wise procedure. No significant as-
sociation was found between any clinical data and BSI
(Additional file 9).
Shifts in the microbiome functional repertoire in patients
who developed subsequent BSI
We also predicted the functional composition of the
fecal microbiome using PICRUSt. This algorithm esti-
mates the functional potential of microbial communities
given the current 16S rRNA gene survey and the set of
currently sequenced reference genomes [15]. PICRUSt
predictions in the human gut microbiome are expected
to be 80–85 % correlated with the true metabolic path-
way abundances. Therefore, the PICRUSt results should
be considered suggestive only. We used LEfSe to identify
significant differences in microbial genes (level 2 and
level 3 KEGG Orthology groups, Linear Discriminant
Analysis score (log10) >2) in the samples collected prior
to treatment from patients who developed and did not
develop subsequent BSI [18]. The fecal microbiome of
Fig. 4 a BSI risk index based on the differentiated taxa (n = 28). We included in the BSI risk index all the taxa with a false discovery rate (FDR)-
corrected p value less than 0.15. The BSI was then calculated using the sum of relative abundances of the taxa that were significantly associated
with BSI minus the sum of the relative abundances of the taxa that were associated with protection from BSI. Mann–Whitney U test: ***p < 0.001.
Boxplots denote top quartile, median, and bottom quartile. BSI, Bloodstream infection. b Receiving-operating characteristic (ROC) curve analysis of
the BSI risk index in fecal samples collected prior to treatment, to differentiate patients who developed subsequent BSI and patients who did not
develop BSI. We applied tenfold jack-knifing; the ten ROC curves are in blue and the mean ROC curve is in black. BSI, Bloodstream infection
Fig. 3 Relative abundance of the differentiated taxa in samples collected prior to treatment in patients who developed subsequent BSI (n = 11)
and patients who did not develop BSI (n = 17). BSI, Bloodstream infection
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patients that developed subsequent BSI were enriched in
functional categories associated with xenobiotics biodeg-
radation and metabolism and depleted in categories
associated with transcription machinery, histidine me-
tabolism, arginine and proline metabolism, lipid biosyn-
thesis proteins and alanine, aspartate and glutamate
metabolism (Additional file 10). Many of these alter-
ations in the metabolic capacity were previously re-
ported to compromise the intestinal epithelial barrier
function, therefore potentially enabling bacterial trans-
location [19–22].
Discussion
Decreased diversity in pretreatment samples predicts BSI
A previous study found that mean measures of microbial
diversity decreased over the course of HSCT [10]. An-
other recent study reported that reduced diversity, mea-
sured the day of the transplant, predicted the patients
that will die during the HSCT procedure [23]. Reduced
diversity of fecal microbiota in inflammatory states is
well documented [24]. In a murine model of ileal
Crohn’s disease (CD), induction of inflammation was as-
sociated with reduced microbial diversity and mucosal
invasion by opportunistic pathogen [25]. Our findings
provide further evidence that a diverse microbiome is as-
sociated with protection from BSI [26]. Furthermore, we
demonstrate that decreases in gut microbial diversity are
observed before patients even begin treatment. This
suggests that certain patients may be predisposed to
infection prior to entering the hospital and that we can
identify these patients using their microbiota.
Barnesiellaceae-enriched fecal microbiota is protective
against BSI
In mice colonized with vancomycin-resistant Entero-
coccus (VRE), a recent study demonstrated that
recolonization with microbiota that contain Barnesiella
correlates with VRE clearance [27]. Moreover, in patients
undergoing HSCT, intestinal colonization with Barne-
siella was associated with resistance to Enterococcal
domination, a risk factor for subsequent VRE BSI [10, 27].
Our findings support that this taxon is required to prevent
expansion of oxygen-tolerant bacteria, such as Entero-
coccus and Enterobacteriaceae, the most frequent blood-
stream pathogens in patients undergoing HSCT [28].
Barnesiellaceae was also decreased in patients with HIV
compared to a healthy control group [29]. Barnesiella was
found to be negatively correlated to TNF-α, markers of
systemic inflammation in HIV patients [19]. Furthermore,
Barnesiella was decreased in case of severe colitis in
IL-22–deficient and co-housed wild-type mice, sug-
gesting its protective role against inflammation [20].
In our findings, Barnesiella is an important member
of the BSI protection-associated taxa, although there
are several other taxa that are strongly associated
with protection or risk of BSI.
Ruminococceae-depleted fecal microbiota lead to BSI
Faecalibacterium prauznitzii, major member of the genus
Faecalibacterium, is a well-described anti-inflammatory
organism, considered to be a marker of GI health [24]. A
recent study of cirrhotic patients showed that patients
who presented a bacterial translocation had a lower ratio
of F. prausnitzii/E. coli as compared to patients who did
not have sepsis [21]. Additionally, Oscillospira was in-
creased in microbiomes amended with Christensenella
minuta for prevention of adiposity [30]. Oscillospira has
also been reported to directly regulate components in-
volved in the maintenance of gut barrier integrity [22].
Ruminococceae-modulated microbes were butyrate-
producing bacteria. Butyrate is a short-chain fatty acid
that has a key function in intestinal epithelium devel-
opment [31]. Butyrate was previously reported to exhibit
anti-inflammatory properties by reducing permeability of
the intestinal epithelium. In addition, it has been proposed
that butyrate can reinforce colonic defense barriers by
increasing antimicrobial peptide levels and mucin pro-
duction [9].
Other BSI-protective taxa are associated with healthy
states in published datasets
Christensenellaceae was enriched in fecal samples of
healthy individuals when compared to pediatric and
young adult IBD patients and in lean when compared to
obese participants [30]. Christensenella was reported to
be significantly depleted in fecal samples of ulcerative
colitis patients [32], in fecal samples of patients with
post-infectious irritable bowel syndrome [33], and in pa-
tients with CD relative to healthy controls [24]. A study
demonstrated that Desulfovibrio is a common sulfate-
reducing bacteria found in the fecal microbiota of
healthy individuals, harboring positive effects on the gut
barrier integrity [34]. The Butyricimonas genus, known
as a butyrate producer with anti-inflammatory effects,
was found decreased in the untreated multiple sclerosis
patients as compared with healthy participants [35]. Sut-
terella was also found decreased in CD patients [24].
BSI-associated taxa are linked to gut inflammation in
published datasets
Veillonella has been previously associated with intestinal
inflammation in CD patients [24]. Moreover, Veillonella
was found enriched in in Clostridium difficile infection
patients when compared to healthy controls [36]. Erysi-
pelotrichaceae was described as one of the drivers of ex-
acerbated intestinal inflammation in a mouse model of
IBD [37]. Furthermore, in colorectal cancer patients and
in a murine model of inflammation-associated colorectal
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cancer, Erysipelotrichaceae was associated with the in-
flammation and colonic tumorigenesis [38].
Motivation for the predictive risk index model
The goal of a supervised learning method is to learn a
function of some combination of predictors, such as the
relative abundances of bacterial taxa, that correctly pre-
dicts an experimental outcome, such as BSI incidence.
In microbiome data, this is a hard problem from a statis-
tical perspective because the classifier must determine
which taxa to include in the model and how much
weight to assign to each taxon. Choosing which predic-
tors to include from a large set of features is called
feature selection. The problem becomes even more com-
plicated when there are non-linear relationships between
the taxa and the outcome, and when there are statistical
dependencies between the taxa. Different types of classi-
fiers have different levels of flexibility for incorporating
these types of relationships. In general, the more param-
eters or degrees of freedom available to the classifier, the
more flexible it is, but the larger the training set it re-
quires to avoid over-fitting. Therefore, it is common to
choose classifiers that have built-in constraints that keep
them from being too flexible.
For example, if we were to fit a logistic regression to the
relative abundances of all 176 genera observed in our data,
using 27 of the 28 samples for training, the model would
grossly overfit the training data and would not be likely to
classify the held-out sample correctly on average. On the
other hand, if we only based our model on the single most
discriminative genus, then we would fail to account for
inter-individual variation in genus membership and the
potential for convergent evolution to allow different taxa
to perform the same functions in different people, and
again we would not expect good predictive performance.
The goal is to find a good method that is neither too flex-
ible (too many degrees of freedom) nor too constrained
(too few degrees of freedom). A common solution to the
problem of over-fitting is to force most of the regression
coefficients to be very small by constraining their sum-of-
squares or their sum-of-absolute-values to be less than a
particular threshold. However, determining the correct
threshold requires the use of a nested cross-validation
procedure. In this and other recent analyses, we have
found that a simple approach to feature selection using
the univariate Mann–Whitney U test does a good job of
identifying useful predictors without the need for nested
cross-validation to tune model parameters.
Furthermore, once a subset of predictors has been
identified, in smaller datasets it may be challenging sta-
tistically to learn the correct regression coefficients for
each of the predictors. Instead, we reasoned that in the
absence of sufficient data for determining proper regres-
sion coefficients, a good proxy for the strength of an
association between a taxon and a clinical phenotype of
the host is simply its relative abundance. Therefore, we
chose to use the additive risk index as our predictive
model, which is equivalent to a linear model in which all
of the regression coefficients are 1 (for risk-associated
taxa), −1 (for protection-associated taxa), or 0 (for taxa
not identified as significant using the Mann–Whitney U
test). This approach is consistent with the theory of
convergent evolution, in which multiple different species
may be occupying the same ecological niche in different
human individuals, under the assumption that the niche
population sizes are relatively consistent across species.
Another benefit is that, in contrast to a ratio-based risk
index, the additive index can easily produce meaningful
scores when a patient is completely lacking either the
protection-associated taxa or the risk-associated taxa. It
is important to note that the larger the microbiome
dataset, the more likely it is that a more complex classi-
fier will provide better predictive accuracy on held-out
data. However, many clinical microbiome datasets are
still limited in size due to limitations of patient recruit-
ment and funding, in which case the additive risk index
may be a useful alternative to more complex and more
flexible supervised learning models.
Alternatives to fecal-microbiota transplant therapy in
immunocompromised patients
Our findings demonstrate that there is a predictive rela-
tionship between pre-chemotherapy gut microbiome
and future risk of BSI in patients with NHL receiving
allogeneic transplantation. To the extent that gut micro-
biome does contribute to BSI risk, future management
of patients submitted to HSCT procedure may include
administration of microbiome-targeting therapeutics to
decrease risk of infectious complications. One obvious
strategy would be fecal microbiota transplantation from
a healthy donor or even from preserved donation of the
patient’s own microbiota. However, this therapeutic ap-
proach may lead to exposure to unknown pathogens
and/or potential transfer of a risk-associated microbiota,
not to mention microbiota that may predispose the
recipient to various microbiome-linked diseases [39].
Therefore, we proposed an alternative strategy: to select
a consortium of OTUs expected have protective and
beneficial effects on the host that could be administered
to the patients during the HSCT procedure. A clear next
step is to evaluate a consortium of microbial taxa for its
ability to prevent or decrease risk of BSI.
Our study has several limitations. First, our cohort is
limited to patients with NHL receiving allogeneic HSCT.
Thus, our BSI risk index prediction may not be
generalizable to other chemotherapy regimens, other
hematological malignancies, and other immunocom-
promised patients, although it is suggestive that similar
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approaches could apply in those populations. The next
step will be to validate the performance of the BSI risk
index presented here in a larger cohort of patients with
other hematological malignancies and receiving different
types of chemotherapy regimen. Second, patients
received various cancer-specific treatments before HSCT
procedure that may affect pre-HSCT microbiome com-
position, although we did not find an association between
clinical history and BSI risk. Third, sequence coverage per
sample was somewhat low for one sample (3041
sequences), although a previous study showed that large
effects can be recovered with as few as 100 or even 10
sequences per sample [40]. Here we showed that alpha-
and beta-diversity findings were retained even when
subsampling data were down to very shallow depths of
500 sequences per sample. To avoid throwing out data
contained in the higher depth samples for the taxon asso-
ciation and risk index analyses, we used the normalized
relative abundances from full-depth samples in place of
rarefied data.
Conclusions
Identifying cancer patients at high risk for BSI is a signifi-
cant clinical challenge and is an important step toward re-
ducing morbidity and mortality during the early transplant
period. Our 16S rRNA gene sequencing-based analysis
showed that a significant shift in microbial community
structure precedes BSI, even before chemotherapy begins.
Our findings also suggest the possibility of preventive
manipulation of the intestinal microbiota to reduce risk of
life-threatening infection in immunocompromised patients
undergoing HCST. Based on our results we recommend
future research into the development of a microbiome-
targeted therapy to prevent BSI.
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